TY - JOUR
T1 - Outcome of healing after dental implant placement in patients with cancer on high-dose antiresorptive medications
T2 - a prospective feasibility study
AU - Andersen, Sanne Werner Møller
AU - Ottesen, Camilla
AU - Gotfredsen, Klaus
AU - Jensen, Simon Storgård
AU - Kofod, Thomas
AU - Schiodt, Morten
N1 - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2023/3
Y1 - 2023/3
N2 - PURPOSE: Implant placement in patients with cancer receiving high-dose antiresorptive medication (HDAR) is considered contraindicated. This prospective, feasibility study tested the hypothesis that dental implants can be placed in such patients by applying a staged implant placement protocol with submerged healing.METHODS: Three groups of patients on HDAR were included as follows: group 1: patients who underwent tooth extraction, without the development of medication-related osteonecrosis of the jaws (MRONJ); group 2: patients with surgically treated MRONJ who had demonstrated clinical healing for at least 3 months; group 3: patients with established MRONJ who was planned for surgical resection and simultaneous implant placement.RESULTS: A total of 49 implants were placed in 27 patients (group 1: 12, group 2: 7 and group 3: 8). HDAR included bisphosphonates and denosumab. The mean HDAR time was 25 months (SD: ± 18.4, range 3-68 months). An abutment operation was performed 4 months following the implant placement (SD: ± 1.9, range 3-14 months). All patients healed uneventfully.CONCLUSIONS: This study demonstrated that it is feasible to insert dental implants and perform an abutment surgery in patients with cancer on HDAR, without the development of MRONJ.CLINICALTRIALS: gov Identifier: NCT04741906.
AB - PURPOSE: Implant placement in patients with cancer receiving high-dose antiresorptive medication (HDAR) is considered contraindicated. This prospective, feasibility study tested the hypothesis that dental implants can be placed in such patients by applying a staged implant placement protocol with submerged healing.METHODS: Three groups of patients on HDAR were included as follows: group 1: patients who underwent tooth extraction, without the development of medication-related osteonecrosis of the jaws (MRONJ); group 2: patients with surgically treated MRONJ who had demonstrated clinical healing for at least 3 months; group 3: patients with established MRONJ who was planned for surgical resection and simultaneous implant placement.RESULTS: A total of 49 implants were placed in 27 patients (group 1: 12, group 2: 7 and group 3: 8). HDAR included bisphosphonates and denosumab. The mean HDAR time was 25 months (SD: ± 18.4, range 3-68 months). An abutment operation was performed 4 months following the implant placement (SD: ± 1.9, range 3-14 months). All patients healed uneventfully.CONCLUSIONS: This study demonstrated that it is feasible to insert dental implants and perform an abutment surgery in patients with cancer on HDAR, without the development of MRONJ.CLINICALTRIALS: gov Identifier: NCT04741906.
KW - Antiresorptive agents
KW - Cancer
KW - Dental implant
KW - Prosthodontics
KW - Prospective Studies
KW - Humans
KW - Bisphosphonate-Associated Osteonecrosis of the Jaw/diagnostic imaging
KW - Dental Implants
KW - Neoplasms/chemically induced
KW - Bone Density Conservation Agents/adverse effects
KW - Feasibility Studies
UR - http://www.scopus.com/inward/record.url?scp=85123915855&partnerID=8YFLogxK
U2 - 10.1007/s10006-022-01042-5
DO - 10.1007/s10006-022-01042-5
M3 - Journal article
C2 - 35084584
SN - 1865-1550
VL - 27
SP - 89
EP - 100
JO - Oral and Maxillofacial Surgery
JF - Oral and Maxillofacial Surgery
IS - 1
ER -